NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
SurvivorNet on MSN
Muscle invasive bladder cancer: Understanding your treatment options
Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder ...
Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results